Christian Rolfo, MD, Ph.D., MBA, Dr.hc., Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai. In this video, he speaks about Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?
Â
Â
Overview:
Â
Agents that target immunological checkpoints have shown promise in improving therapy outcomes in patients with lung cancer in a variety of clinical settings over the last few years. The FDA has approved PD-1/PD-L1 inhibitors alone or in combination with chemotherapy or other immune checkpoint inhibitors, such as anti-CTLA-4 drugs, for the treatment of several forms of lung cancer. The introduction of these drugs into clinical practice has transformed lung cancer treatment, maintaining the promise of long-term benefit in certain patient populations. Immunotherapy’s therapeutic indications in lung cancer are quickly expanding, and several combinations have either entered clinical practice or are in the early stages of the investigation. Furthermore, the search for a reliable predictive biomarker to overcome the limitations of already approved diagnostics for patient selection is also continuing. The present status and progress of anti-PD-1/PD-L1 medicines in lung cancer treatment were summarized in this review.